Dr. Govind Babu

Dr. Govind Babu is a distinguished Medical Oncologist with extensive experience in the diagnosis and treatment of solid tumors and hematological malignancies. He has received advanced specialty training from the world-renowned Dana-Farber Cancer Institute and MD Anderson Cancer Center, USA.

Dr. Babu is recognized for his expertise in systemic cancer therapies, including chemotherapy, immunotherapy, hormone therapy, targeted therapy, and precision medicine. His patient-centered approach focuses on delivering personalized treatment plans using the latest advances in cancer care to achieve the best possible clinical outcomes.

Expertise

Dr. Govind Babu specializes in the comprehensive medical management of solid tumors and blood cancers through advanced systemic cancer therapies.

• Chemotherapy.
• Immunotherapy.
• Targeted Therapy.
• Hormone Therapy.
• Precision Oncology.
• Treatment of Solid Tumors.
• Management of Hematological Malignancies.
• Personalized Cancer Treatment Planning.

Training & Certifications

• Advanced Specialty Training – Dana-Farber Cancer Institute, USA.
• Advanced Specialty Training – MD Anderson Cancer Center, USA.

Leadership & Recognition

• President – Indian Society of Medical and Pediatric Oncology (ISMPO).
• President – SAARC Federation of Oncology.
• Co-Chair – ESMO India Summit 2020.
• Recipient of several national and international awards in oncology.
• Investigator and contributor to numerous national and international clinical oncology trials.
• Author of more than 60 national and international scientific publications.

Research & Publications

Dr. Govind Babu has made significant contributions to oncology research through more than 60 peer-reviewed national and international publications. His research spans breast cancer, hematological malignancies, head and neck cancers, targeted therapy, precision oncology, chronic myeloid leukemia, immunotherapy, and clinical practice guidelines. He has also actively participated in numerous multicenter clinical trials, helping advance evidence-based cancer care and innovative treatment strategies.